Covetrus, a private-equity-backed tech company for veterinary practices, is in preliminary talks to purchase Cencora Inc.'s veterinary business, according to a Bloomberg report from late Friday. CD&R, ...

Simply sign up to the Private equity myFT Digest -- delivered directly to your inbox. Private equity group Clayton Dubilier & Rice is preparing to put industrials company Indicor up for sale aiming ...

Clayton Dubilier & Rice and TPG Inc. are in talks with private credit firms including Blue Owl Capital Inc. to line up at least $2.5 billion of debt for Covetrus, a technology company for veterinary ...

Clayton Dubilier & Rice is seeking $26 billion for its latest flagship private equity fund, an ambitious target that would count among the industry’s largest-ever fundraises. CD&R has begun ...

US-based packaging producer Sealed Air has confirmed that the 30-day 'go-shop' period linked to its agreed sale to funds affiliated with Clayton, Dubilier & Rice (CD&R) has expired. The update follows ...

CHARLOTTE - Sealed Air Corporation (NYSE:SEE) announced Wednesday that the 30-day "go-shop" period related to its pending acquisition by funds affiliated with CD&R has expired with no alternative ...

Sealed Air's (SEE) sale to CD&R could see some investor pushback as the price is likely below expectations, according to a Wolfe Research analyst. "We sense that the deal value is below most buy-side ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The acquisition deal comes after ...

As per the deal, shareholders will receive $42.15 per share in cash, reflecting a 41% premium to Sealed Air's closing price on August 14, 2025. The purchase price also represents a 24% premium to the ...

Boehringer Ingelheim and CDR-Life have entered into a global licensing agreement for CDR111, a trispecific T-cell engager developed by CDR-Life for the treatment of autoimmune diseases. CDR111 is an ...

Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody. In return ...